Fig. 3.

PFS and OS among renal cell carcinoma according to baseline NLR (a, b) and NLR variations between the first and the fourth administration (c, d). a Is referring to the PFS of patients of the renal cell carcinoma cohort according to the baseline NLR value (below or above the median NLR baseline value in the renal cell carcinoma cohort). b Is referring to the OS of patients of the renal cell carcinoma cohort according to the baseline NLR value (below or above the median NLR baseline value in the renal cell carcinoma cohort). c Is referring to the PFS of patients of the renal cell carcinoma cohort according to the NLR variation between the first and the fourth nivolumab administration. d Is referring to the OS of patients of the renal cell carcinoma cohort according to the NLR variation between the first and the fourth nivolumab administration